Ekaterina Trishkina

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

J.F.R. Robertson, Igor Bondarenko, Ekaterina Trishkina et al. · The Lancet · 2016 · 580 citations · Full text

Mg Versus, Breast Oncology, Oncology +8

Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

Xavier Pivot, Igor Bondarenko, Zbigniew Nowecki et al. · Journal of Clinical Oncology · 2018 · 95 citations

Surgical Oncology, Breast Oncology, Cancer Management +21

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results

Xavier Pivot, Igor Bondarenko, Zbigniew Nowecki et al. · European Journal of Cancer · 2018 · 68 citations · Full text

A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer.

Xavier Pivot, Igor Bondarenko, Mikhail Dvorkin et al. · Journal of Clinical Oncology · 2017 · 18 citations

Sb3 Vs Trz, Tpcr Rate, Surgical Oncology +15

FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer

Matthew J. Ellis, Igor Bondarenko, Ekaterina Trishkina et al. · Annals of Oncology · 2016 · 15 citations

Breast Oncology, Medicine, Phase Iii +8